Clinical Trial Update: Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301) [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and tolerability of POD-DHE (INP104) for migraine; results have been posted following completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• POD-DHE (INP104) (DHE-based therapy POD-DHE)

Snippet

Sponsor: Impel Pharmaceuticals | Conditions: Migraine Headache | Phase 3 | Status: COMPLETED | Results posted: 2021-02-12